ESPRIT (European/Australasian Stroke Prevention in Reversible Ischaemia Trial)
Background
Results of trials of dipyridamole and ASA combined versus ASA alone for the secondary prevention of vascular events after ischaemic stroke of presumed arterial origin are inconsistent. The aim of the ESPRIT investigators was to resolve this uncertainty.
Disclaimer
ESPRIT is an independent investigator initiated study ESPRIT describes the use in a composite endpoint which is not part of the Aggrenox® (Asasantin®) label
The dose range of ASA in ESPRIT was 30-325mg/day; on average less than 75mg/day
83% of the patients received dipyridamole; 8% the fixed-dose combination ER-dipyridamole + ASA 200/25mg twice daily, marketed as Aggrenox® and Asasantin® retard
